Barclays PLC Raises Stock Position in STAAR Surgical (NASDAQ:STAA)

Barclays PLC lifted its position in STAAR Surgical (NASDAQ:STAA - Free Report) by 349.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 91,707 shares of the medical instruments supplier's stock after purchasing an additional 71,301 shares during the period. Barclays PLC owned about 0.19% of STAAR Surgical worth $3,406,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Mutual of America Capital Management LLC boosted its holdings in shares of STAAR Surgical by 214.7% during the second quarter. Mutual of America Capital Management LLC now owns 26,459 shares of the medical instruments supplier's stock worth $1,260,000 after purchasing an additional 18,051 shares during the period. ClariVest Asset Management LLC bought a new position in STAAR Surgical during the 2nd quarter valued at approximately $1,223,000. Algert Global LLC lifted its holdings in STAAR Surgical by 13.5% in the 2nd quarter. Algert Global LLC now owns 116,655 shares of the medical instruments supplier's stock worth $5,554,000 after buying an additional 13,901 shares during the period. HighTower Advisors LLC bought a new stake in shares of STAAR Surgical in the 3rd quarter worth approximately $336,000. Finally, Granite Investment Partners LLC bought a new stake in shares of STAAR Surgical in the 2nd quarter worth approximately $17,237,000. 96.70% of the stock is owned by hedge funds and other institutional investors.

STAAR Surgical Stock Up 3.3 %

NASDAQ STAA traded up $0.80 during trading on Tuesday, hitting $24.97. 210,119 shares of the stock traded hands, compared to its average volume of 702,364. The company has a market capitalization of $1.23 billion, a P/E ratio of 56.75 and a beta of 0.59. STAAR Surgical has a 12-month low of $23.72 and a 12-month high of $52.68. The firm has a 50-day simple moving average of $28.00 and a 200-day simple moving average of $34.25.

Analysts Set New Price Targets

STAA has been the subject of several research analyst reports. Stifel Nicolaus dropped their target price on shares of STAAR Surgical from $50.00 to $44.00 and set a "buy" rating for the company in a research report on Monday, August 26th. Stephens upgraded shares of STAAR Surgical to a "hold" rating in a report on Monday, December 2nd. Canaccord Genuity Group cut their price objective on STAAR Surgical from $31.00 to $28.00 and set a "hold" rating on the stock in a research report on Monday, December 9th. Finally, Needham & Company LLC reissued a "hold" rating on shares of STAAR Surgical in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $42.83.

Insider Buying and Selling

In related news, major shareholder Broadwood Partners, L.P. purchased 53,500 shares of the firm's stock in a transaction dated Monday, December 16th. The stock was purchased at an average price of $24.24 per share, with a total value of $1,296,840.00. Following the completion of the purchase, the insider now owns 10,821,931 shares of the company's stock, valued at approximately $262,323,607.44. The trade was a 0.50 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 1.00% of the stock is currently owned by corporate insiders.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.